Merck and Moderna report their mRNA melanoma vaccine cuts the risk of recurrence in a confirmatory trial, the clearest evidence yet that personalized cancer vaccines work, not just that they might.
Merck and Moderna report their mRNA melanoma vaccine cuts the risk of recurrence in a confirmatory trial, the clearest evidence yet that personalized cancer vaccines work, not just that they might.